Iovance Biotherapeutics Inc Forecast, price target & analysts
Iovance Biotherapeutics Inc Target price 2025 - Analyst rating & recommendation
Iovance Biotherapeutics Inc Classifications & Recommendation:
Iovance Biotherapeutics Inc Price Target
| Target Price | $20.36 |
| Price | $3.51 |
| Potential |
480.16%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Iovance Biotherapeutics Inc 2026 .
The average Iovance Biotherapeutics Inc target price is $20.36.
This is
480.16%
register free of charge
$32.00
811.68%
register free of charge
$5.00
42.45%
register free of charge
|
|
| A rating was issued by 13 analysts: 12 Analysts recommend Iovance Biotherapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Iovance Biotherapeutics Inc stock has an average upside potential 2026 of
480.16%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 164.07 | 452.92 |
| 13,687.39% | 176.05% | |
| EBITDA Margin | -214.34% | -51.53% |
| 99.40% | 75.96% | |
| Net Margin | -238.14% | -52.88% |
| 99.51% | 77.79% |
10 Analysts have issued a sales forecast Iovance Biotherapeutics Inc 2025 . The average Iovance Biotherapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Iovance Biotherapeutics Inc EBITDA forecast 2025. The average Iovance Biotherapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Iovance Biotherapeutics Inc Analysts have issued a net profit forecast 2025. The average Iovance Biotherapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.28 | -0.78 |
| 32.28% | 39.06% | |
| P/E | negative | |
| EV/Sales | 1.95 |
11 Analysts have issued a Iovance Biotherapeutics Inc forecast for earnings per share. The average Iovance Biotherapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Iovance Biotherapeutics Inc...
Current Iovance Biotherapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Apr 14 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Apr 14 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
